ALK-Abello A/S, of Copenhagen, Denmark, said partner Torii Pharmaceutical Co. Ltd., of Tokyo, has submitted a new drug application in Japan for ALK's house dust mite sublingual allergy immunotherapy tablet for the indication of allergic rhinitis.